Dr. Reddy’s Laboratories Allots New Shares Under Employee Stock Option SchemeTip Ranks·1 day ago, 01:27 PMRDY+0.08%
Dr Reddy’s gets four USFDA observations at Bachupally formulations plant after GMP inspectionPUBT·Aug 17 at 05:41 AMRDY+0.08%
Dr. Reddy’s API and Services CEO Deepak Sapra resigns, set to exit in NovemberPUBT·Aug 13 at 08:56 AMRDY+0.08%
Zacks Research Issues Optimistic Forecast for RDY EarningsMarket Beat·Aug 12 at 05:42 AMRDY+0.08%MS+0.14%
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseasesPUBT·Aug 11 at 07:20 AMCOYA-1.44%RDY+0.08%
Dr. Reddy’s Ends Novartis India Brand Distribution Pact, Plans Transition by September 2026Tip Ranks·Aug 10 at 11:48 AMRDY+0.08%NVS-0.40%
Innoviva Q2 FY26 swings to net loss of $83.4 million; revenue rises 19% to $119.6 millionPUBT·Aug 5 at 03:28 PMINVA+0.43%RDY+0.08%
Sei Investments Co. Increases Stock Position in Dr. Reddy's Laboratories Ltd $RDYMarket Beat·Aug 4 at 03:40 AMRDY+0.08%
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States | RDY Stock NewsStockTitan·Aug 3 at 04:39 PMRDY+0.08%MRK-1.05%
Fresenius Kabi wins FDA approval for Rituxan biosimilar in US marketPUBT·Aug 3 at 01:29 AMFSNUY0.00%FRE
Dr. Reddy's registers PD-1 inhibitor in South Africa for recurrent or metastatic nasopharyngeal carcinomaPUBT·Aug 3 at 02:11 AMRDY+0.08%
